30results about "Fused cells" patented technology

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.

Provided herein are cells, enzymes, and methods for improved cannabinoid production.

A cell culture device according to the present disclosure comprises: a culture chamber for culturing suspension cells; a flow path having a culture medium supply port and a culture medium discharge port, and provided adjacent to part or all of the outer side of at least one surface of the culture chamber; an oxygen permeable membrane provided to at least part of the flow path and / or the culture chamber; and a cell seeding port provided to at least part of the culture chamber.

The present invention provides isolated polypeptides capable of specifically binding to a protein target selected from LGALS9, CRP, BTLA, SAA, EGF, or FGA, or to a peptide thereof, especially under urinary conditions, which may be used for predicting in a urine sample of a subject suspected of having an infection whether the infection is a bacterial infection or a viral infection. The present invention further provides methods of diagnostics and treatment using the isolated polypeptides, and suitable diagnostic kits.

Provided are a bispecific antibody containing an anti-CLDN18.2 antibody, and a pharmaceutical composition and the use thereof. The bispecific antibody comprises a fist protein functional region and a second protein functional region, wherein the first protein functional region is an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, and the second protein functional region targets a target different from CLDN18.2 (for example, CD47). The bispecific antibody has a good biological activity and anti-tumor application prospects.

The present invention aims to provide a radiolabeled anti-CDH3 antibody having an excellent antitumor effect and a cancer therapeutic agent containing the same. The present invention relates to a 225 Ac-labeled anti-CDH3 antibody and a cancer therapeutic agent containing the same.

This disclosure provides, among other things, a transgenic chicken. In some embodiments, the transgenic chicken comprises B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding a heavy chain variable domain in which the CDR3 is in the range of 30-60 amino acids in length and comprises at least 2 cysteine residues; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the heavy chain variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene.

The application belongs to the technical field of biological medicine, and particularly relates to a curcuma-mesenchymal stem cell fusion exosome and application thereof in treating diabetic wounds. The curcuma exosome and the mesenchymal stem cell exosome are fused by a short-time and low-power ultrasonic fusion technology of an ultrasonic instrument on a mixed exosome suspension, and a fusion exosome is prepared. The fusion exosome is further prepared into a fusion exosome gel, so that the problem of low delivery efficiency of the exosome and the mesenchymal stem cell exosome when used alone is improved, and the healing effect of the diabetic wound is significantly improved.

This invention provides a method for separating cells from a culture medium in bioprocesses, particularly biopharmaceutical processes. [Solution] A method for separating cells from a culture medium, comprising: a culture step of culturing cells in a culture medium 14 in a bioreactor; a filtration step of filtering the culture medium 14 in a filtration module 16 having at least one membrane, wherein the culture medium 14 passes through a recirculation circuit; and a rinsing step of rinsing the membrane during filtration with a rinsing solution, wherein the rinsing solution is introduced into the recirculation circuit by rinsing.

The present disclosure provides compositions such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells that include and / or modulate the expression or activity of cancer-related proteins in various embodiments. The present disclosure also provides methods for treating cancer using agents that include and / or modulate the expression or activity of cancer-related proteins in various embodiments and methods for identifying such agents. In some embodiments, the agent includes a target protein identified herein (e.g., a target protein listed in the Sequence Listing, Table A, or a variant of the foregoing).

Provided is a (N1+N2)-ploid pluripotent stem cell comprising a fused cell of a N1-ploid (wherein N1 represents an integer of 2 to 16) pluripotent stem cell and a N2-ploid (wherein N2 represents an integer of 2 to 16) pluripotent stem cell.

Provided in the present invention is a T cell receptor engineering modification method, which comprises the steps of: obtaining CDR regions of a given T cell receptor sequence by means of a database, mutating one or more amino acid residues in the CDR regions into histidine, and establishing a first T cell receptor mutation library. The T cell receptor engineering modification method provided by the present invention is based on a histidine scanning method, realizes TCR engineering modification independent of three-dimensional structures, overcomes the disadvantages of high affinity and realizes the modification of TCRs with low affinity and high activation, thereby providing more options for clinical use. The T cell receptor provided by the present invention comprises the following six CDR regions, CDR1α, CDR2α and CDR3α in a TCRα chain, and CDR1β, CDR2β and CDR3β in a TCRβ chain, the amino acid sequences of which are shown as SEQ ID No. 1-6, respectively. In the present invention, engineering modification of a wild-type MAGE-A3 TCR molecule is achieved by means of a catch bond to obtain an efficient and non-toxic TCR targeting MAGE-A3, which is free of toxic and side effects caused by affinity maturation. Moreover, the engineered TCR is applied to TCR-T cell preparation for solid tumor treatment.

Described herein are methods and compositions for producing heterologous proteins. Heterologous proteins can include sweet proteins and sweet polypeptides. For examples, described herein are expression cassettes, including, for example, promoters and signal peptides, for recombinantly expressing a recombinant sweet protein in a host cell.

Provided are an anti-CLDN18.2 antibody, and a pharmaceutical composition and the use thereof. Specifically, provided is an anti-CLDN18.2 antibody or an antigen-binding fragment thereof. The anti-CLDN18.2 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein the amino acid sequence of HCDR1 is as shown in SEQ ID NO: 5, the amino acid sequence of HCDR2 is as shown in SEQ ID NO: 6, and the amino acid sequence of HCDR3 is as shown in SEQ ID NO: 7; and the amino acid sequence of LCDR1 is as shown in SEQ ID NO: 8, the amino acid sequence of LCDR2 is as shown in SEQ ID NO: 9, and the amino acid sequence of LCDR3 is as shown in SEQ ID NO: 10. The anti-CLDN18.2 antibody has a good biological activity and anti-tumor application prospects.

The invention relates to monoclonal antibodies which specifically bind to the TRBV9 family of human T-cell receptors. The invention also relates to a nucleic acid which codes for said antibody or for an antigen-binding fragment thereof, to an expression vector, to a method for producing the antibody, and to the use of said antibody for treating diseases or disorders associated with the family of human T-cell receptors. The invention is directed towards producing antibodies that can be used for eliminating T-cells carrying T-cell receptors of the TRBV9 family, in particular for treating ankylosing spondylitis, coeliac disease, and blood cancers, in the pathogenesis of which T-cell receptors of the TRBV9 family are involved.

The present disclosure relates to a nucleic acid sequence that confers expression of an insecticidal protein when introduced into a cell, as well as related compositions and methods of use thereof. In some aspects, the present disclosure provides a plant comprising the nucleic acid sequence.

To provide antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful for diagnosing cancer and / or determining whether cancer cells express CLDN6.SOLUTION: The present invention provides an antibody or an antigen-binding fragment thereof, which binds to a peptide having a specific amino acid sequence, and / or to claudin 6 (CLDN6), wherein the antibody or antigen-binding fragment thereof binds to CLDN6 by binding at least to an epitope within CLDN6 having a specific amino acid sequence.SELECTED DRAWING: None

Provided herein are methods of reducing expression of host cell proteins during a mammalian cell culture process using peroxisome proliferator–activated receptor γ (PPARγ) modulator and / or an autophagy-inducing compounds.

This invention provides an antagonist for human thymic stromal lymphoid neogenetic factor (TSLP), which is expected to be useful in treating inflammatory and fibrotic disorders. [Solution] This disclosure provides compositions and methods relating to antigen-binding proteins that bind to TSLP, including antibodies. In certain embodiments, this disclosure provides fully human anti-TSLP antibodies, humanized anti-TSLP antibodies and chimeric anti-TSLP antibodies, as well as derivatives of such antibodies. This disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, as well as methods for producing and using such antibodies (including methods for treating and preventing TSLP-related inflammatory and fibrotic disorders).

To provide a method capable of preventing complication of a safety problem such as immunogenicity and complication of a purification step in culture of animal cells, by suppressing increase of a protein production amount, suppressing generation of misfolded / coagulated protein, suppressing generation of a deamidation body of a protein and a substitution / deficiency body of an amino acid through adjustment and optimization of a cell culture condition related to protein production.SOLUTION: The invention relates to a production method of a fusion protein comprising an IgG Fc domain, in particular, the invention is configured so that, in a production method of a fusion protein comprising the IgG Fc domain, a step for culturing cells which produce the fusion protein at a lowered culture temperature, is added, for increasing cell growth and cell survival rate, for increasing productivity of the fusion protein and suppressing generation of an aggregate, and for improving quality and production yield.SELECTED DRAWING: Figure 1

The object of the present invention is to provide a detecting agent for specifically detecting a tumor cell, a tumor antigen peptide-specifically presented on a tumor cell, a pharmaceutical composition useful for the prevention and / or treatment of cancer, the pharmaceutical composition containing the tumor antigen peptide as an active ingredient, etc. The above object has been achieved by a tumor antigen peptide or its motif-substituted product, the tumor antigen peptide comprising 8 to 14 consecutive amino acids in an amino acid sequence of a protein encoded by a gene selected from the group consisting of PVT1, SUV39H2, ZNF724P, SNRNP40, and DYRK4, the tumor antigen peptide having an HLA binding ability.

This disclosure provides TrkA agonist antibodies, compositions comprising such antibodies, and methods of using such antibodies for the prevention and / or treatment of a disease or disorder.

The present disclosure provides a cell culture device comprising: a culture chamber for culturing suspension cells; a first flow path adjacent to the culture chamber, and having a first culture medium supply port and a first culture medium discharge port; a second flow path having a second culture medium supply port and a second culture medium discharge port; a semi-permeable membrane disposed in at least a portion between the first flow path and the second flow path; and a seeding port provided to at least a portion of the culture chamber.

Disclosed herein include methods, compositions, and kits suitable for use in generation of genome-expanded organisms comprising, e.g., a chimeric genome. In some embodiments, the methods, systems and nucleic acid compositions include systems comprising a donor cell comprising one or more components of a delivery module and a recipient cell comprising one or more components of an integrator module. In some embodiments, the methods, systems and nucleic acid compositions comprise polynucleotides encoding one or more components of a delivery module, and one or more components of an integrator module.

The present invention provides an IL13RA2-targeting herpes simplex virus in which an anti-IL13RA2 antibody or an antigen-binding fragment thereof is presented on the viral surface. Also provided is an anti-IL13RA2 antibody or an antigen-binding fragment thereof capable of specifically recognizing tumor cells.

The present disclosure relates to a method for producing recombinant proteins (e.g., monoclonal antibodies) having high productivity, product quality, and robust functional activity in rat hybridoma cells (e.g., YB2 / 0) by modifying cell culture process parameters and / or basal medium and feed combinations. The present disclosure also relates to the commercial scale production (e.g., 10,000 L to 25,000 L) of recombinant proteins (e.g., monoclonal antibodies) in rat hybridoma cells. The present disclosure also relates to recombinant proteins (e.g., monoclonal antibodies) and compositions (e.g., pharmaceuticals) having unique glycosylation profiles produced using the methods disclosed herein.

This disclosure provides antibodies or antigen-binding moieties that specifically bind to antigens related to myelomatous malignancies, various compositions of such antibodies or antigen-binding moieties, and methods for using them. The disclosure provides such antibodies, fragments of such antibodies that retain myelomatous malignancy antigen-binding ability, pharmaceutical compositions comprising such antibodies or antigen-binding fragments, and diagnostic compositions comprising such antibodies or antigen-binding fragments. The disclosure further provides isolated nucleic acids encoding such antibodies, amino acid sequences of such antibodies, and host cells transformed thereby. In addition, the disclosure provides therapeutic and diagnostic methods using the antibodies and nucleic acids of the disclosure. Finally, the disclosure provides recombinant bispecific antibodies capable of specifically binding to CG1 and CD3.

The present invention provides isolated polypeptides including antibodies capable of specifically binding CRP or CRP -derived peptides under urinary conditions, methods of using such isolated polypeptides and antibodies in diagnostics of inflammation, and kits including them.

To provide a method for generating a recombinant mammalian cell expressing a heterologous polypeptide, and a method for producing a heterologous polypeptide using the recombinant mammalian cell, wherein in the recombinant cell, the expression of the endogenous SIRT-1 gene has been reduced.SOLUTION: The reduction in the expression of the endogenous SIRT-1 gene in a recombinant cell, for example, the knockout of the sirtuin-1 gene (SIRT-1) in mammalian cells, such as CHO cells, improves recombinant productivity and reduces lactate production by the cells.SELECTED DRAWING: None

The present invention addresses the problem of providing a grafting-improving agent, and the problem can be solved by a grafting-improving agent comprising at least one component selected from the group consisting of (a) Nicotiana benthamiana β-1,4-glucanase comprising the amino acid sequence A represented by SEQ ID NO: 1, (b) a β-1,4-glucanase comprising an amino acid sequence B for a β-1,4-glucanase gene belonging to a clade including only a gene for the amino acid sequence A among Nicotiana benthamiana genes in a plant gene tree, (c) a β-1,4-glucanase comprising an amino acid sequence C that has a 90% or higher identity with the amino acid sequence A or the amino acid sequence B, and (d) an expression promotor for the Nicotiana benthamiana β-1,4-glucanase (a), the β-1,4-glucanase (b) or the β-1,4-glucanase (c).